No Data
AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer
AstraZeneca (AZN) Receives a Buy From Goldman Sachs
TRUQAP (Capivasertib) Combination in PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer Demonstrated Statistically Significant and Clinically Meaningful Improvement in Radiographic Progression-free Survival in CAPItello-281 Phase III Trial
AstraZeneca's Truqap Combo Demonstrated Statistically Significant Improvement
GCAR and AstraZeneca Execute Agreement to Evaluate AZD1390 for Glioblastoma
AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
loading...